Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Transl Allergy
Asıl Yazarlar: de Brito, Marianne, Huebner, Gisela, Murrell, DedeeF, Bullpitt, Peter, Hartmann, Karin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Letter to the Editor
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6149008/
https://ncbi.nlm.nih.gov/pubmed/30258566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-018-0222-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller